Lake Street initiated coverage of Monopar Therapeutics (MNPR) with a Buy rating and $106 price target Monopar is preparing to file a New Drug Application for ALXN1840 for Wilson’s Disease a rare, inherited genetic disorder of copper metabolism, in early 2026, notes the analsyt. Based on the firm’s assumption of 5,000 U.S. patients, it forecasts 2033 U.S. ALXN1840 sales of greater than $900M, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Therapeutics management to meet virtually with Piper Sandler
- Promising Long-Term Efficacy and Safety of ALXN1840 Strengthens Buy Rating for Monopar Therapeutics Inc.
- Monopar Therapeutics Presents New Data on ALXN1840
- Monopar Therapeutics Inc’s ALXN1840: A Promising Breakthrough in Wilson Disease Treatment Justifying Buy Rating
- Monopar Therapeutics announces new data from study of ALXN1840